These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 5041685)

  • 1. Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.
    Muenter MD; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1972 Jun; 47(6):389-95. PubMed ID: 5041685
    [No Abstract]   [Full Text] [Related]  

  • 2. 3-methoxy-4-hydroxyphenylalanine (3-O-methyldopa) in plasma during oral L-dopa therapy of patients with Parkinson's disease.
    Sharpless NS; Muenter MD; Tyce GM; Owen CA
    Clin Chim Acta; 1972 Mar; 37():359-69. PubMed ID: 5022100
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of parkinsonian syndromes and plasmatic DOPA levels. Effects of L-DOPA and 3-OMD, administered alone or combined, with or without a decarboxylase inhibitor].
    Geissbühler F; Gaillard JM; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Rev Eur Etud Clin Biol; 1972 Jan; 17(1):38-44. PubMed ID: 5041348
    [No Abstract]   [Full Text] [Related]  

  • 4. L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects.
    Muenter MD; Tyce GM
    Mayo Clin Proc; 1971 Apr; 46(4):231-9. PubMed ID: 5573818
    [No Abstract]   [Full Text] [Related]  

  • 5. 3-O-Methyldopa, L-dopa, and trihexyphenidyl in the treatment of Parkinson's disease.
    Muenter MD; Dinapoli RP; Sharpless NS; Tyce GM
    Mayo Clin Proc; 1973 Mar; 48(3):173-83. PubMed ID: 4570387
    [No Abstract]   [Full Text] [Related]  

  • 6. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 7. [Parkinsonism and plasma metabolism of dihydroxyphenylalanine administered with an inhibitor of decarboxylase].
    Geissbühler F; Constantinidis J; Eisenring JJ; Krassoievitch M; Yanniotis G; Tissot R
    Clin Chim Acta; 1971 Jun; 33(1):111-5. PubMed ID: 5097993
    [No Abstract]   [Full Text] [Related]  

  • 8. [Study of 3-4-dihydroxyphenylacetic acid, a dopamine catabolite, in patients with Parkinson's disease before treatment with L-dopa].
    Samson M; Bohuon C; Augustin P; Comoy E; Pouliquen A
    Rev Neurol (Paris); 1972 Aug; 127(2):315-7. PubMed ID: 4666641
    [No Abstract]   [Full Text] [Related]  

  • 9. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486).
    Yahr MD; Duvoisin RC; Mendoza MR; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1971; 96():55-8. PubMed ID: 5159129
    [No Abstract]   [Full Text] [Related]  

  • 10. Alpha-methyldopa as an adjunct to levodopa treatment of Parkinson's disease.
    Sweet RD; Lee JE; McDowell F
    Trans Am Neurol Assoc; 1971; 96():59-65. PubMed ID: 5159130
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral L-dopa treatment of parkinsonism.
    Andén NE; Carlsson A; Kerstell J; Magnusson T; Olsson R; Roos BE; Steen B; Steg G; Svanborg A; Thieme G; Werdinius B
    Acta Med Scand; 1970 Apr; 187(4):247-55. PubMed ID: 4911257
    [No Abstract]   [Full Text] [Related]  

  • 12. DOPA in Parkinson's disease.
    Lancet; 1969 Apr; 1(7600):871-2. PubMed ID: 4180531
    [No Abstract]   [Full Text] [Related]  

  • 13. L-DOPA treatment in Parkinson's disease: effect on dopamine and related substances in discrete brain regions.
    Davidson L; Lloyd K; Dankova J; Hornykiewicz O
    Experientia; 1971 Sep; 27(9):1048-9. PubMed ID: 5116129
    [No Abstract]   [Full Text] [Related]  

  • 14. A method for the determination of dopa and 3-O-methyldopa in the plasma of Parkinsonian patients.
    Curzon G; Kantamaneni BD; Trigwell J
    Clin Chim Acta; 1972 Mar; 37():335-41. PubMed ID: 5022098
    [No Abstract]   [Full Text] [Related]  

  • 15. Amino acid and dopa levels in plasma and urine from L-dopa-treated patients with Parkinson's disease.
    Hare TA; Vanna S; Beasley B; Chambers R; Vogel WH
    J Lab Clin Med; 1971 Feb; 77(2):319-25. PubMed ID: 5540775
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dopa metabolism in relation to the therapy of Parkinson's syndrome].
    Pletscher A; Bartholini G
    Actual Pharmacol (Paris); 1971; 24():27-49. PubMed ID: 5150621
    [No Abstract]   [Full Text] [Related]  

  • 17. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 18. L-dopa therapy in parkinsonism: mechanism of action.
    Sandler M
    Psychiatr Neurol Neurochir; 1971; 74(4):331-3. PubMed ID: 5146239
    [No Abstract]   [Full Text] [Related]  

  • 19. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 20. Absence of response to levodopa in Parkinson's disease.
    Mones RJ
    JAMA; 1971 Aug; 217(9):1245. PubMed ID: 5109470
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.